Rho-associated kinase activity is a predictor of cardiovascular outcomes

Hypertension

Volumn 63, Issue 4, 2014, Pages 856-864

  Kajikawa, Masato ^a   Noma, Kensuke ^b,c   Maruhashi, Tatsuya ^a   Mikami, Shinsuke ^a   Iwamoto, Yumiko ^a   Iwamoto, Akimichi ^a   Matsumoto, Takeshi ^a   Hidaka, Takayuki ^a   Kihara, Yasuki ^a   Chayama, Kazuaki ^a   Nakashima, Ayumu ^c   Goto, Chikara ^d   Liao, James K ^e   Higashi, Yukihito ^b,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; biological markers; cardiovascular events; cardiovascular risk factors; Rho associated kinase

Indexed keywords

RHO KINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REVASCULARIZATION; WESTERN BLOTTING;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR EVENTS; CARDIOVASCULAR RISK FACTORS; RHO-ASSOCIATED KINASE;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RHO-ASSOCIATED KINASES; RISK FACTORS;

EID: 84897082342     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02296     Document Type: Article

References (42)

1. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
2. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K. Formation of actin stress fbers and focal adhesions enhanced by Rho-kinase. Science. 1997;275:1308-1311.
3. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514.
4. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, Ambrosio G. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104:2039-2044.
5. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273:245-248.
6. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, Hiroi Y, Shimizu K, Luscinskas FW, Sun J, Liao JK. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest. 2008;118:1632-1644.
7. Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre JS, Esposito B, Merval R, Groux H, Loirand G, Tedgui A. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res. 2003;93:884-888.
8. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, Inoue M, Masatsugu K, Saito T, Fukunaga Y, Sakaguchi S, Arai H, Ohno N, Komeda M, Nakao K. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000;101:2030-2033.
9. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui M, Kaibuchi K, Shimokawa H, Takeshita A. Important role of Rho-kinase in the pathogenesis of cardiovascular infammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 2002;39:245-250.
10. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, Liao JK. Decreased perivascular fbrosis but not cardiac hypertrophy in ROCK1+/-haploinsuffcient mice. Circulation. 2005;112:2959-2965.
11. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001;38:1307-1310.
12. Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, Bittar N, Weiss RJ, Morales-Ballejo H, Thadani U; Fasudil Study Group. Effcacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46: 1803-1811.
13. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002;105:1545-1547.
14. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, Nakano T. Benefcial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J. 2006;70:174-178.
15. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, Tagawa T, Shimokawa H, Takeshita A, Sunagawa K. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation. 2005;111:2741-2747.
16. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E; Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci. 2005;238:31-39.
17. Noma K, Goto C, Nishioka K, Hara K, Kimura M, Umemura T, Jitsuiki D, Nakagawa K, Oshima T, Chayama K, Yoshizumi M, Higashi Y. Smoking, endothelial function, and Rho-kinase in humans. Arterioscler Thromb Vasc Biol. 2005;25:2630-2635.
18. Soga J, Hata T, Hidaka T, Fujii Y, Idei N, Fujimura N, Mikami S, Maruhashi T, Kihara Y, Chayama K, Kato H, Noma K, Liao JK, Higashi Y, for ROCK Investigator Group. Rho-associated kinase (ROCK) activity, endothelial function and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2011; 31:2353-2359.
19. American Diabetes Association. Clinical practice recommendations 1999. Diabetes Care. 1999; 22(suppl 1):S1-S114.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.
21. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators Developing the Japanese Equation for Estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53: 982-992.
22. Shin HK, Salomone S, Potts EM, Lee SW, Millican E, Noma K, Huang PL, Boas DA, Liao JK, Moskowitz MA, Ayata C. Rho-kinase inhibition acutely augments blood fow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab. 2007;27:998-1009.
23. Ding J, Li QY, Wang X, Sun CH, Lu CZ, Xiao BG. Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial infammatory responses in mice. J Neurochem. 2010;114:1619-1629.
24. Satoh S, Toshima Y, Hitomi A, Ikegaki I, Seto M, Asano T. Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res. 2008;1193: 102-108.
25. Feske SK, Sorond FA, Henderson GV, Seto M, Hitomi A, Kawasaki K, Sasaki Y, Asano T, Liao JK. Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res. 2009;1257:89-93.
26. Pasterkamp G, van Lammeren GW. Pleiotropic effects of statins in atherosclerotic disease. Expert Rev Cardiovasc Ther. 2010;8:1235-1237.
27. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767-775.
28. Nohria A, Prsic A, Liu PY, Okamoto R, Creager MA, Selwyn A, Liao JK, Ganz P. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009;205:517-521.
29. Fujimura N, Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Mikami S, Maruhashi T, Iwamoto Y, Kihara Y, Chayama K, Kato H, Noma K, Liao JK, Higashi Y, for ROCK Investigator Group. Selective mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with essential hypertension. Clin Pharmacol Therapeut. 2012;91:289-297.
30. Hoshijima M, Sah VP, Wang Y, Chien KR, Brown JH. The low molecular weight GTPase Rho regulates myofbril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem. 1998;273:7725-7730.
31. Wei L, Imanaka-Yoshida K, Wang L, Zhan S, Schneider MD, DeMayo FJ, Schwartz RJ. Inhibition of Rho family GTPases by Rho GDP dissociation inhibitor disrupts cardiac morphogenesis and inhibits cardiomyocyte proliferation. Development. 2002;129:1705-1714.
32. Thorburn J, Xu S, Thorburn A. MAP kinase-and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J. 1997;16:1888-1900.
33. Kawamura S, Miyamoto S, Brown JH. Initiation and transduction of stretch-induced RhoA and Rac1 activation through caveolae: cytoskeletal regulation of ERK translocation. J Biol Chem. 2003;278:31111-31117.
34. Chang J, Xie M, Shah VR, Schneider MD, Entman ML, Wei L, Schwartz RJ. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apopto-sis. Proc Natl Acad Sci USA. 2006;103:14495-14500.
35. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res. 2006;98:730-742.
36. Wang YX, da Cunha V, Martin-McNulty B, Vincelette J, Li W, Choy DF, Halks-Miller M, Mahmoudi M, Schroeder M, Johns A, Light DR, Dole W P. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E defcient mice. Eur J Pharmacol. 2005;512:215-222.
37. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Zhu W, Kadowaki T, Yazaki Y. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res. 1999;84:458-466.
38. Sah VP, Hoshijima M, Chien KR, Brown JH. Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem. 1996;271:31185-31190.
39. Hines WA, Thorburn A. Ras and rho are required for galphaq-induced hypertrophic gene expression in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 1998;30:485-494.
40. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, Liao JK, Creager MA. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res. 2006;99:1426-1432.
41. Liu P Y, Chen JH, Lin LJ, Liao JK. Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol. 2007;49:1619-1624.
42. Kikuchi Y, Yasuda S, Aizawa K, Tsuburaya R, Ito Y, Takeda M, Nakayama M, Ito K, Takahashi J, Shimokawa H. Enhanced Rho-kinase activity in circulating neutrophils of patients with vasospastic angina: a possible bio-marker for diagnosis and disease activity assessment. J Am Coll Cardiol. 2011;58:1231-1237.